ESAB Earnings: What To Look For From ESAB

ESAB (NYSE: ESAB) is set to report earnings Thursday before market hours. Last quarter, ESAB posted revenue of $745.6 million, up 9.9% year on year, but missed analysts on EPS. For the upcoming quarter, analysts expect about 10% revenue growth. The article cites an average price target of $135.40 versus a $94.76 share price.

Original reporting
Published Aug 5, 2026, 4:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:23 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ESAB Earnings: What To Look For From ESAB — source image
Decision brief

The 30-second read

$ESABNeutralMed
01

Why it matters

Traders can use the stated consensus revenue growth (10% YoY) and the note that analysts reconfirmed estimates to position for a potential beat or miss, but the article lacks any new guidance or revisions.

02

Market read

This is primarily a pre-earnings checklist for ESAB, anchored on consensus revenue growth and recent estimate behavior, with peer results as context.

03

What to watch

The article does not mention order backlog, guidance for the next quarter, margin trajectory, or cash flow, which are often the true drivers of post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: ahead of ESAB earnings this Thursday before market hours

Background

ESAB is a welding and cutting equipment manufacturer, and the article previews its upcoming earnings with prior-quarter context and peer read-across.

Company-level read

Ticker impact

$ESABNeutralMedium confidence
Context

ESAB is set to report earnings this Thursday pre-market, with the article citing revenue expectations and recent estimate reconfirmations.

Expected impact

Likely limited edge for trading unless ESAB’s actual EPS and revenue growth diverge from the stated consensus.

Evidence & confidence

Actionable timing is present (earnings scheduled), but the article does not disclose fresh guidance, revisions, or a new catalyst beyond what is already known (prior-quarter beat/miss and consensus growth rate).

Market effects

Professional tools and equipment peers’ recent results are used as a read-across, implying investors may anchor on similar demand trends.

No specific regional demand or macro linkage is provided.

No explicit global supply chain or international demand catalyst is discussed.

Counterpoint

If peers’ results were mixed, ESAB could still outperform on margins or orders even with revenue growth near consensus, making the EPS miss less predictive.

Key entities

  • ESAB

    Subject of the earnings preview, including prior-quarter revenue/EPS context and upcoming earnings timing.

  • Stanley Black & Decker

    Peer cited for its flat YoY revenue and meeting expectations, used as a read-across.

  • Hyster-Yale Materials Handling

    Peer cited for a 15% YoY revenue decline that topped estimates, used as a read-across.

Related articles

$ESABMed

ESAB’s (NYSE:ESAB) Q2 CY2026 Sales Beat Estimates

ESAB (NYSE:ESAB) reported Q2 CY2026 revenue of $807.6 million, up 12.9% year over year, exceeding Wall Street estimates by 2.6%. Non-GAAP EPS was $1.33, down from $1.36 a year earlier and 3% below consensus. Operating margin fell to 9.7% from the prior year. Analysts expect full-year EPS to rise from $5.31 to $6.08.

$ESABHigh

ESAB Corp (ESAB): Results of Operations and Financial Condition

ESAB Corp (ESAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document ESAB Corporation Announces Second Quarter 2026 Results • Record total sales increased 12.9%, with core organic sales up 2.5% • Core organic growth in both segments • Closed Eddyfi ahead of schedule • Updating 2026 outlook

$ESABMed

Q4 Results 29th May Live: Asian Paints, IndiGo, NMDC, Glenmark Pharma, Ipca Lab, IREDA, Gujarat Gas, Natco Pharma, Inox Wind, Rubicon Research, BEML, NMDC Steel, JM Financial, Triveni Engg to announce

The article previews Q4 results from multiple Indian companies and highlights several earnings updates. Prime Focus reported standalone net profit of Rs 4.32 crore for March 2026 quarter vs Rs 16.11 crore loss a year earlier. Alkem Laboratories’ standalone net profit fell to Rs 217 crore from Rs 276.9 crore; it recommended a final dividend of Rs 10/share. It also cites Q4FY26 figures for ESAB India, Ecos Mobility, and Ivalue Infosolutions, plus early stock moves.

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.